ClinicalTrials.gg
CompletedNCT01425008Updated Aug 10, 2020Results posted

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

A Phase 1 interventional study of MLN2480 in Melanoma, Metastatic Melanoma and Solid Tumor, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
149
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
316th of 1,749
149 · median 37
Started
2011
with 78 others
Phase 1
647 of 2,049
54 open now
Registered
759th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 316th largest by enrollment of the 1,749 interventional ones that give a count, is one of 79 that started in 2011, is one of 647 in phase 1, and was the 759th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.

03

Conditions studied

  • Melanoma
  • Metastatic Melanoma
  • Solid Tumor
  • Neoplasm

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. .
  2. Male or female participants 18 years or older.
  3. Dose Escalation phase: Participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies of for whom no approved therapy is available.
  4. Dose Expansion phase: melanoma (locally advanced or metastatic melanoma).
  5. Dose Expansion phase: At least 1 which has not been treated previously with radiotherapy. A newly arising lesion in a previously irradiated field is acceptable.
  6. For participants undergoing procedures: (PT) and activated partial thromboplastin time (aPTT) must be within the normal range.
  7. (ECOG) performance status less than or equal to (\<=) 1.
  8. Adequate tissue sample from either archival formalin-fixed paraffin-embedded (FFPE) tumor tissue or new biopsy of tumor.
  9. Previous chemotherapy, immunotherapy, and hormone therapy must be completed at least 4 weeks prior to the administration of MLN2480 and radiation must be completed at least 3 weeks prior to the administration of MLN2480; all associated toxicity must be resolved to \<=Grade 1.
  10. Expected survival time of at least 3 months in the opinion of the investigator.
  11. Participants who do not have hypo- or hyperthyroidism.
  12. Ability to swallow and retain oral medication.
  13. Female participants who are for at least 1 year, surgically sterile, or agree to practice 2 effective methods of through 3 months after the last dose of study drug or agree to practice true abstinence.
  14. Male participants who, even if surgically sterilized, agree to practice effective barrier contraception through 3 months after the last dose of alisertib or agree to practice true abstinence.

Exclusion criteria

Exclusion Criteria

  1. History of any major disease that might interfere with safe protocol participation.
  2. Dose Expansion phase: Previous treatment with RAF or MEK inhibitors.
  3. Laboratory values as specified in study protocol.
  4. Current enrollment in any other treatment study.
  5. Evidence of current uncontrolled cardiovascular conditions within the past 6 months.
  6. Prior investigational agents for malignant or non-malignant disease within 4 weeks prior to Day 1.
  7. Active hepatitis or (HIV) infection.
  8. Active bacterial or viral infection.
  9. Female participants who are pregnant or currently breastfeeding.
  10. Major surgery within 28 days of Day 1.
  11. nausea and vomiting, malabsorption, or significant bowel or stomach resection.
  12. Inability to comply with study requirements.
  13. Other unspecified reasons that, in the opinion of the investigator or Millennium, make the participant unsuitable for enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    MLN2480

    Drug: MLN2480

Interventions

  • Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.

    Also known as: TAK-580

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths

    Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)

  2. Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)

    Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.

    Time frame: Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])

  3. Number of Participants With TEAEs Related to Physical Examination Findings

    Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)

  4. Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)

    Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)

  5. Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)

  6. Eastern Cooperative Oncology Group (ECOG) Performance Score

    ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(\>) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair \>50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.

    Time frame: at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)

  7. Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis

    Time frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.

    Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)

  2. Progression-free Survival (PFS)

    PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.

    Time frame: Baseline up to the date of first document PD, or death due to any cause, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)

  3. Duration of Response (DOR)

    DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.

    Time frame: From the first documented response (CR or PR) up to the date of first documented PD (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)

  4. Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580

    Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 hours [h]) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)

  5. Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580

    Time frame: Escalation and Expansion Q2D Cohorts: C1D21 pre-dose (C=22 days [Escalation Q2D] and 28 days [Expansion Q2D]); Escalation QW Cohorts: C1D22 pre-dose (C= 28 days)

  6. Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580

    Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)

  7. Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580

    Time frame: Escalation (Esc.) and Expansion (Exp.) Q2D: C1D21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D22 at multiple time-points (up to168 h) post-dose (C=28 days)

  8. Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580

    Time frame: Q2D Cohorts: Cycle1 Days 1 and 21 up to 24 hours post-dose (Cycle1 length= 22 days); QW Cohorts: Cycle2 Days 1 and 22 up to 7 hours post-dose (Cycle 2 length= 28 days)

  9. Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580

    Time frame: Cycle 1 Days 1 and 21 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length= 22 days)

  10. QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580

    Time frame: Cycle 1 Days 1 and 22 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)

  11. Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points

    The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.

    Time frame: Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])

  12. Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points

    The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.

    Time frame: Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])

07

Results

Posted Aug 10, 2020

Participant flow

Participants took part in the study at 16 investigative sites in the United States and United Kingdom from 13 September 2011 to 16 October 2018.

Dose Escalation Phase
Participant flow — Dose Escalation Phase
MilestoneQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive
Started43337733134000000000
Completed0000000000000000000
Not completed43337733134000000000
Withdrew: Progressive disease2323540262000000000
Withdrew: Adverse event2000020020000000000
Withdrew: Unsatisfactory therapeutic response0000102110000000000
Withdrew: Withdrawal by subject0000111010000000000
Withdrew: Symptomatic deterioration0010000022000000000
Withdrew: Other0000000010000000000
Dose Expansion Phase
Participant flow — Dose Expansion Phase
MilestoneQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive
Started000000000016816161120219
Completed0000000000100000000
Not completed000000000015816161120219
Withdrew: Progressive disease0000000000104121589210
Withdrew: Withdrawal by subject0000000000100001100
Withdrew: Other0000000000001000204
Withdrew: Symptomatic deterioration0000000000210001201
Withdrew: Adverse event0000000000233011503
Withdrew: Lost to follow-up0000000000000000100
Withdrew: Unsatisfactory therapeutic response0000000000000000001

Outcome measures

PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths
Time frame:
Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths
ParticipantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
TEAEs4333773313416816161120192
SAEs20102412539651241182
Deaths1010010021022000101
PrimaryDose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)

Dose limiting AEs were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Dose limiting AEs were defined as any of the following events: Grade 4 neutropenia for more than 7 days under maximum supportive therapy; febrile neutropenia; platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; if Course 2 was not initiated within 14 days due to AE related to the protocol treatment; Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (example, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.

Time frame:
Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)
ParticipantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)
Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)0000020002
PrimaryNumber of Participants With TEAEs Related to Physical Examination Findings
Time frame:
Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Related to Physical Examination Findings
ParticipantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Weight decreased0000010020110012120
Weight increased0000000000001000300
Breath sounds abnormal0000001000000000000
PrimaryClinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)
Time frame:
Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Reported as:
Mean · kilogram (kg)
Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)
kilogram (kg)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Baseline87.477 ± 15.779472.077 ± 8.216267.375 ± 17.337177.717 ± 4.169576.963 ± 21.902677.695 ± 14.324769.522 ± 17.693773.589 ± 13.253481.054 ± 23.690780.503 ± 15.740195.837 ± 30.288771.288 ± 8.657081.312 ± 17.473657.100 ± NA75.267 ± 15.323172.847 ± 23.843979.624 ± 16.609883.298 ± 16.369567.000 ± NA
Change at EOSV7.167 ± 16.0315-1.693 ± 1.44681.542 ± 1.1139-0.907 ± 1.36980.065 ± 1.4543-0.544 ± 3.10330.272 ± 1.6037-1.225 ± 4.5746-1.868 ± 4.8255-1.270 ± 0.0005-7.825 ± 20.1782-1.700 ± 6.2386-3.164 ± 3.7607—-3.225 ± 2.98260.201 ± 3.7358-4.292 ± 6.5671-3.189 ± 3.9690—
PrimaryNumber of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings
Time frame:
Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings
ParticipantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings0000000000000000000
PrimaryEastern Cooperative Oncology Group (ECOG) Performance Score

ECOG performance score was measured on 6 point scale to assess participant's performance status, where: 0 (fully active, able to carry on all pre-disease activities without restriction); 1 (restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); 2 (ambulatory greater than(\>) 50 percent (%) of waking hours), capable of all self-care, unable to carry out any work activities); 3 (capable of only limited self-care, confined to bed or chair \>50% of waking hours); 4(completely disabled, cannot carry on any self-care, totally confined to bed or chair); 5 (dead). A higher score indicated greater functional impairment.

Time frame:
at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Reported as:
Mean · score on a scale
Eastern Cooperative Oncology Group (ECOG) Performance Score
score on a scaleQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Eastern Cooperative Oncology Group (ECOG) Performance Score1.0 ± 0.001.0 ± 1.001.7 ± 1.530.3 ± 0.581.3 ± 0.491.2 ± 0.451.0 ± 0.000.7 ± 0.581.0 ± 0.471.0 ± 0.000.7 ± 0.731.5 ± 0.580.6 ± 0.90—0.8 ± 0.411.2 ± 0.980.6 ± 0.740.7 ± 0.802.0 ± NA
PrimaryNumber of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis
Time frame:
Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis
ParticipantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Liver function analyses0000000000325033522
Skeletal and cardiac muscle analyses0000000000812005611
Mineral and electrolyte analyses0000000000230000211
Tissue enzyme analyses NEC0000000000003012101
Renal function analyses0000010000001001400
Platelet analyses0000000010001000300
White blood cell analyses0000000000100000301
Red blood cell analyses0000100000110010000
Pituitary analyses anterior0001000000100010000
Carbohydrate tolerance analyses (incl diabetes)0000000000000000100
Cardiac function diagnostic procedures0000000000001000000
Coagulation and bleeding analyses0000100000000000000
Digestive enzymes0000000010000000000
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). The ORR assessment was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30% decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.

Time frame:
Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Overall Response Rate (ORR)00000000133350177000000
SecondaryProgression-free Survival (PFS)

PFS was the time from first dose date of study drug to date of the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. The PFS assessment was based on RECIST 1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. Participants with no response assessment were censored at the date of first dose.

Time frame:
Baseline up to the date of first document PD, or death due to any cause, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Progression-free Survival (PFS)1.4 (0.8 to NA)1.4 (1.0 to 1.4)1.4 (1.0 to 1.5)1.4 (1.4 to 1.4)1.5 (1.3 to 2.8)1.2 (0.9 to 32.5)NA (NA to NA)9.2 (0.8 to 9.2)1.5 (0.7 to 1.9)1.9 (1.0 to NA)5.7 (1.9 to 14.3)2.4 (1.0 to 3.7)1.8 (1.8 to 3.2)0.8 (NA to NA)1.9 (1.8 to 2.2)1.8 (1.7 to 5.5)3.6 (1.8 to NA)2.3 (1.9 to 5.5)1.7 (1.6 to 1.8)
SecondaryDuration of Response (DOR)

DOR was assessed from the first documented response (CR or PR) to the date of first documented PD and was censored at the date of the last assessment for responders who died without documented PD and for responders who were still alive and had not progressed. DOR assessment was based on RECIST v1.1. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. DOR was calculated using Kaplan-Meier estimate.

Time frame:
From the first documented response (CR or PR) up to the date of first documented PD (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle =28 days] in Expansion Phase)
Reported as:
Median · months
Duration of Response (DOR)
monthsQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Duration of Response (DOR)————————NA (NA to NA)NA (NA to NA)6.0 (3.7 to NA)NA (NA to NA)1.5 (NA to NA)——————
SecondaryDose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580
Time frame:
Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 hours [h]) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Cmax: Maximum Observed Plasma Concentration for TAK-580
nanogram per milliliter (ng/mL)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: Pharmacokinetic Cohort
Cycle 1 Day 1140.0 ± 86.61393.1 ± 49.81921.7 ± 332.401048.1 ± 290.911933.6 ± 717.032675.2 ± 1296.952072.8 ± 287.292934.0 ± 690.394459.3 ± 1475.086774.3 ± 1082.791606.9 ± 670.48
Cycle 1 Day 21301.5 ± 61.83759.7 ± 138.592038.8 ± 1076.993321.5 ± 1275.833809.1 ± 466.854063.1 ± 782.334588.4 ± 700.04———3548.8 ± 1310.21
Cycle 1 Day 22———————3135.2 ± 485.704739.8 ± 2902.536460.2 ± 1632.31—
SecondaryDose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580
Time frame:
Escalation and Expansion Q2D Cohorts: C1D21 pre-dose (C=22 days [Escalation Q2D] and 28 days [Expansion Q2D]); Escalation QW Cohorts: C1D22 pre-dose (C= 28 days)
Reported as:
Mean · ng/mL
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Ctrough: Trough Concentration for TAK-580
ng/mLQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: Pharmacokinetic Cohort
Cycle 1 Day 21178.3 ± 42.92265.5 ± 74.251080.0 ± 797.751720.0 ± 708.871739.7 ± 746.882135.0 ± 494.002700.0 ± 1088.94———2085.0 ± 672.26
Cycle 1 Day 22———————270.0 ± 108.00898.7 ± 618.681216.7 ± 841.80—
SecondaryDose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580
Time frame:
Escalation (Esc.) and Expansion (Exp.) Q2D: C1D1 and 21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D1 and 22 at multiple time-points (up to168 h) post-dose (C=28 days)
Reported as:
Median · hour
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, Tmax: Time to Reach the Cmax for TAK-580
hourQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: Pharmacokinetic Cohort
Cycle 1 Day 13.983 (2.00 to 4.07)2.150 (1.98 to 4.05)2.033 (2.00 to 4.00)3.917 (1.18 to 4.02)2.050 (1.00 to 23.82)4.033 (0.97 to 23.00)4.000 (1.98 to 6.02)4.150 (3.20 to 5.12)3.150 (1.00 to 7.88)3.100 (2.12 to 7.27)3.108 (0.98 to 7.58)
Cycle 1 Day 212.000 (2.00 to 4.00)3.050 (2.10 to 4.00)4.050 (2.00 to 6.12)2.000 (1.00 to 2.00)2.992 (1.00 to 8.00)2.808 (1.98 to 4.00)12.792 (2.13 to 23.45)———2.192 (1.87 to 6.17)
Cycle 1 Day 22———————3.150 (2.80 to 3.17)3.033 (2.10 to 23.80)3.950 (2.87 to 7.32)—
SecondaryDose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580
Time frame:
Escalation (Esc.) and Expansion (Exp.) Q2D: C1D21 pre-dose and at multiple time points (up to 48 h) post-dose (C=22 days [Esc. Q2D] and 28 days [Exp. Q2D]); Esc. QW: C1D22 at multiple time-points (up to168 h) post-dose (C=28 days)
Reported as:
Median · hour
Dose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, t1/2z: Terminal Phase Disposition Half-life for TAK-580
hourQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: Pharmacokinetic Cohort
Cycle 1 Day 22———————50.22 (46.4 to 59.3)59.06 (31.1 to 119.2)69.65 (61.6 to 73.0)—
SecondaryDose Escalation Phase and Dose Expansion Pharmacokinetic Cohort, CLr: Renal Clearance for TAK-580
Time frame:
Q2D Cohorts: Cycle1 Days 1 and 21 up to 24 hours post-dose (Cycle1 length= 22 days); QW Cohorts: Cycle2 Days 1 and 22 up to 7 hours post-dose (Cycle 2 length= 28 days)

No measurements were reported for this outcome.

SecondaryQ2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580
Time frame:
Cycle 1 Days 1 and 21 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length= 22 days)
Reported as:
Mean · hour*nanogram per milliliter (h*ng/mL)
Q2D Dose Escalation Phase and Q2D Dose Expansion Pharmacokinetic Cohort, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-580
hour*nanogram per milliliter (h*ng/mL)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)Q2D Dose Expansion Phase: Pharmacokinetic Cohort
Day 14799.7 ± 2570.9511019.7 ± 655.0330562.8 ± 16909.2036061.9 ± 8904.4050946.5 ± 10597.1278993.3 ± 23713.6066799.2 ± 7656.5853522.2 ± 17337.54
Day 2110679.2 ± 2571.8321007.9 ± 3501.8643294.2 ± 10403.7299626.7 ± 29090.62125540.2 ± 46299.79156439.3 ± 26263.33165002.1 ± 19899.97127026.4 ± 38244.03
SecondaryQW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580
Time frame:
Cycle 1 Days 1 and 22 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Reported as:
Mean · h*ng/mL
QW Dose Escalation Phase, AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for TAK-580
h*ng/mLQW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)
Day 1184534.4 ± 50225.97278247.9 ± 128772.92431723.3 ± 106266.40
Day 22199210.4 ± 57957.62339244.8 ± 149201.72477700.2 ± 86620.19
SecondaryDose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points

The extent of phosphorylated extracellular signal-regulated kinase (pERK) staining was assessed in the melanoma expansion cohorts. The level of staining was assessed by a pathologist (semi-H scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99 =low staining; 100 to 199= medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed: 0 to 100 =low staining; 100 to 150= medium staining; 150 to 235= high staining.

Time frame:
Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])
Reported as:
Median · percent change
Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in RAF Inhibition Biomarkers at Specified Time Points
percent changeQ2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
Quant H-score180.0 (-100 to 460)-93.5 (-97 to 1235)-82.0 (-96 to -43)—-51.0 (-97 to -5)-15.0 (-95 to 22)-8.0 (-8 to -8)-71.0 (-71 to -71)
Semi H-score-94.5 (-100 to -89)-80.5 (-100 to 2207)-70.0 (-100 to 603)—-24.5 (-78 to 29)-27.0 (-100 to 0)-12.0 (-12 to -12)-23.0 (-23 to -23)
SecondaryDose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points

The extent of cleaved poly ADP-ribose polymerase (cPARP) and BIM-1 was assessed in the melanoma expansion cohorts. The level of staining was assessed by quantified image analysis (quant H-scores) and by quantified image analysis (quant H-scores). The H-score scale used to interpret data from the pathologist rating was as follows: 0 to 99= low staining; 100 to 199 =medium staining; 200 to 300 =high staining. The H-score scale used to interpret data from the quantified image analysis was as followed in cPARP: 0 to 70= low staining; 70 to 175 =medium staining; 175 to 240 =high staining; BIM-1: 0 to 128= low staining; 128 to 155 =medium staining; 155 to 229 =high staining.

Time frame:
Baseline, Cycle 1 Day 21 (Q2D), and Cycle 1 Day 22 (QW) (Cycle length= 22 days [Q2D] and 28 days [QW])
Reported as:
Median · percent change
Dose Expansion Phase, Melanoma Cohorts: Percent Change From Baseline in Apoptotic Biomarkers at Specified Time Points
percent changeQ2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveQ2D Dose Expansion Phase: TAK-580 (BRAF+)
cPARP Quant H-score—-100.0 (-100 to -93)317.5 (-15 to 650)—-100.0 (-100 to -100)-33.5 (-100 to 200)——
cPARP Semi H-score—-96.0 (-100 to -92)-33.0 (-33 to -33)—-11.0 (-11 to -11)-48.0 (-100 to 0)——
BIM-1 Quant H-score265.0 (265 to 265)136.0 (64 to 650)158.0 (90 to 625)—-52.5 (-65 to -40)-23.5 (-53 to 66)35.5 (-29 to 100)960.0 (960 to 960)
BIM-1 Semi H-score723.5 (47 to 1400)64.5 (-84 to 2533)64.0 (30 to 287)—-41.0 (-75 to -7)-17.0 (-49 to 28)-3.5 (-15 to 8)—

Adverse events

Collected over TEAEs are AEs that started after the first dose of study drug and no more than 30 days after the last dose of study drug (approximately Cycle 38 Days 52 [Q2D] and 58 [QW] in Escalation Phase; Cycle 49 Day 58 in Expansion Phase). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)1/4 (25%)2/4 (50%)4/4 (100%)
Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)0/3 (0%)0/3 (0%)3/3 (100%)
Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)0/3 (0%)0/3 (0%)3/3 (100%)
Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)0/7 (0%)2/7 (28.6%)7/7 (100%)
Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)0/3 (0%)1/3 (33.3%)3/3 (100%)
QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)0/3 (0%)2/3 (66.7%)3/3 (100%)
QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)2/13 (15.4%)5/13 (38.5%)12/13 (92.3%)
QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)1/4 (25%)3/4 (75%)4/4 (100%)
Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)0/16 (0%)9/16 (56.3%)16/16 (100%)
Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)2/8 (25%)6/8 (75%)8/8 (100%)
Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)2/16 (12.5%)5/16 (31.3%)16/16 (100%)
Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)0/1 (0%)1/1 (100%)1/1 (100%)
Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive0/6 (0%)2/6 (33.3%)6/6 (100%)
Q2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated0/11 (0%)4/11 (36.4%)11/11 (100%)
Q2D Dose Expansion Phase: Pharmacokinetic Cohort1/20 (5%)11/20 (55%)19/20 (95%)
Q2D Dose Expansion Phase: TAK-580 (BRAF+)1/2 (50%)2/2 (100%)2/2 (100%)
QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive0/19 (0%)8/19 (42.1%)19/19 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive
Pleural effusionRespiratory, thoracic and mediastinal disorders0/40/30/30/30/70/70/30/30/130/40/160/80/161/10/60/111/201/21/19
ConstipationGastrointestinal disorders0/40/30/30/30/70/70/30/30/130/40/161/80/161/10/60/110/200/20/19
InfectionInfections and infestations0/40/30/30/30/70/70/30/30/130/40/160/80/160/10/60/110/201/20/19
Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/30/30/70/70/30/30/130/40/161/80/160/10/60/110/201/20/19
Gastrooesophageal reflux diseaseGastrointestinal disorders0/40/30/30/30/70/70/31/30/130/40/160/80/160/10/60/111/200/20/19
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/31/30/30/70/70/30/30/130/40/160/80/160/10/60/110/200/20/19
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/30/30/70/71/30/30/130/40/160/80/160/10/60/110/200/20/19
Haemorrhage intracranialNervous system disorders0/40/30/30/30/70/70/31/30/130/40/160/80/160/10/60/110/200/20/19
Respiratory failureRespiratory, thoracic and mediastinal disorders1/40/30/30/30/71/70/30/30/130/40/160/80/160/10/60/110/200/20/19
HaemoptysisRespiratory, thoracic and mediastinal disorders0/40/30/30/30/70/70/30/30/131/40/160/80/160/10/60/111/200/20/19
Most frequent other events
Showing 10 of 316
Most frequent other events
EventQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ Naive
ConstipationGastrointestinal disorders0/41/30/33/33/72/70/30/34/130/412/167/89/160/13/61/116/200/24/19
NauseaGastrointestinal disorders0/40/31/31/32/71/70/31/35/131/45/161/85/160/11/61/1111/202/25/19
VomitingGastrointestinal disorders1/40/30/31/30/71/70/31/32/132/40/160/82/161/12/63/114/201/23/19
Abdominal painGastrointestinal disorders0/40/31/31/31/70/70/31/32/132/42/161/81/161/10/61/113/200/20/19
Rectal haemorrhageGastrointestinal disorders0/40/30/30/30/70/70/30/34/134/40/160/80/160/10/61/110/200/20/19
FatigueGeneral disorders3/41/31/32/36/76/71/33/36/132/45/163/87/160/13/63/1112/201/29/19
PyrexiaGeneral disorders0/40/30/30/31/71/70/30/32/130/47/161/81/160/11/60/112/202/23/19
Pain in extremityMusculoskeletal and connective tissue disorders0/41/30/30/30/70/70/30/31/131/42/162/83/161/12/63/111/200/20/19
Back painMusculoskeletal and connective tissue disorders0/40/30/30/30/71/70/30/32/130/43/160/81/161/11/63/113/200/21/19
Aspartate aminotransferase increasedInvestigations0/40/30/30/30/70/70/30/30/130/42/160/84/160/11/62/115/202/20/19

Baseline characteristics

Safety population included all participants who received at least 1 dose of study drug (TAK-580).

Age, Continuous
Age, Continuous(years)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveTotal
Mean71.0 ± 10.1066.3 ± 8.3356.7 ± 10.2654.7 ± 13.6558.7 ± 14.7765.0 ± 4.4071.0 ± 6.2454.7 ± 13.5857.2 ± 9.3466.8 ± 7.5054.6 ± 12.4458.9 ± 16.3968.4 ± 7.8656.0 ± NA56.7 ± 17.2467.5 ± 8.6965.1 ± 14.6750.5 ± 0.7166.1 ± 11.1362.5 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveTotal
Female322214218265613682973
Male1111631252103100351201076
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveTotal
Hispanic or Latino211012024101000010016
Not Hispanic or Latino111132319314716161117218117
Unknown or Not Reported111233000020000020116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveTotal
American Indian or Alaska Native00000000000000000000
Asian00000000000000001001
Native Hawaiian or Other Pacific Islander00000000000000000000
Black or African American10001100110000000005
White3332663312315816161119219141
More than one race00000000000000000000
Unknown or Not Reported00010000001000000002
Region of Enrollment
Region of Enrollment(Participants)Q2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)Q2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)QW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)Q2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)Q2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)Q2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ NaiveQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreatedQ2D Dose Expansion Phase: Pharmacokinetic CohortQ2D Dose Expansion Phase: TAK-580 (BRAF+)QW Dose Expansion Phase: TAK-580 NRAS WT+ NaiveTotal
United States43337733134601001420011102
United Kingdom0000000000108615702847
08

Study locations

16 sites
  • San Francisco, California, United States
  • Denver, Colorado, United States
  • Augusta, Georgia, United States
  • Indianapolis, Indiana, United States
  • New York, New York, United States
  • Easton, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • San Antonio, Texas, United States
  • Lakewood, Washington, United States
  • Bristol, Avon, United Kingdom
  • Cambridge, Cambridgeshire, United Kingdom
  • Chelmsford, Essex, United Kingdom
  • London, Greater London, United Kingdom
  • Manchester, Greater Manchester, United Kingdom
  • Oxford, Oxfordshire, United Kingdom
  • Newcastle upon Tyne, Tyne & Wear, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment."

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Apr 2017, 66 months.

Results were first posted in Aug 2020, 3 years 3 months after primary completion.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 66 months is above that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2011
First posted
Aug 29, 2011
StartActual
Sep 15, 2011
Primary completionActual
Apr 11, 2017
CompletionActual
Oct 16, 2018
Results first posted
Aug 10, 2020
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01425008
Responsible party
Sponsor
First posted
Aug 29, 2011
Start date
Sep 15, 2011
Primary completion
Apr 11, 2017
Completion
Oct 16, 2018
Results posted
Aug 10, 2020
Last update
Aug 10, 2020

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion